The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
Aims to become India’s leading cancer testing company
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
Krsnaa Diagnostics receives LoI from RINPAS for radiology services
Apulki Healthcare is India's first PPP dedicated for cancer and cardiac care hospita
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
The brand will establish an integrated hearing care ecosystem at Neuberg Diagnostics centers across the length and breadth of the country
Vijaya Diagnostic Centre has reported total income of Rs. 159.78 crores during the quarter ended June 30, 2024
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Subscribe To Our Newsletter & Stay Updated
